Durham, North Carolina, United States, February 2025 – Alcami Corporation (“Alcami”), a leading contract development and manufacturing organization (CDMO), has announced the appointment of Tori E. Arens as President, Drug Product.
In this role, Arens will lead cGMP drug product manufacturing operations at Alcami, overseeing the company’s two sterile fill-finish facilities in Research Triangle Park, North Carolina, and Charleston, South Carolina, as well as its oral solid dose drug product manufacturing, packaging, and labeling facilities in Wilmington, North Carolina.
Patrick Walsh, Chairman and Interim CEO of Alcami, stated: “Tori brings a unique skillset of manufacturing expertise along with strong leadership skills that will be of great value to Alcami, our customers, and their patients alike.”
Tori E. Arens is a proven pharmaceutical manufacturing leader with more than 25 years of experience in drug substance and sterile drug product development, technology transfer, manufacturing, and supply across small molecules, biologics, and gene therapies. She most recently served as Vice President, General Manager, and Site Head for Resilience’s RTP facility for gene therapy viral vector manufacturing. Her past roles include Vice President, Drug Product Manufacturing and Supply at Aerie Pharmaceuticals (now Alcon), Director of Parenteral Operations at Biogen, and Senior Director of Parenteral Operations at Eisai, Inc.
Arens holds both a Master of Science in Pharmaceutics and a Bachelor of Arts in Chemistry from the University of North Carolina at Chapel Hill.
“I’m thrilled to join Alcami during this exciting period of growth and to collaborate with such a talented team,” said Tori E. Arens. “Alcami’s vision, mission, and values deeply resonate with me, and I look forward to leading this area of operations to drive continued success and serve patients worldwide.”
About Alcami
Alcami is a U.S.-based contract development and manufacturing organization (CDMO) with over 45 years of experience in advancing pharmaceuticals and biologics from development to delivery. Alcami offers fully integrated lab services, drug product manufacturing, cGMP pharmaceutical storage, and support services, including environmental monitoring, calibration, and validation. The company is privately owned by GHO Capital, The Vistria Group, and Ampersand Capital Partners.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
